Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688606 vs ISRG, BDX, MDLN: Buyback Yield % Comparison
For the Medical Instruments & Supplies subindustry, Hangzhou Alltest Biotech Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Alltest Biotech Co Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hangzhou Alltest Biotech Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Hangzhou Alltest Biotech Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Alltest Biotech Co (SHSE:688606) has a Buyback Yield % of 0.00 as of Aug. 20, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Hangzhou Alltest Biotech Co and its competitors. According to the industry distribution chart, Hangzhou Alltest Biotech Co ranks #999999 out of 336 companies in the Medical Devices & Instruments industry.
Is Hangzhou Alltest Biotech Co's Buyback Yield % too high?
Hangzhou Alltest Biotech Co's current Buyback Yield % is 0.00. Based on the distribution chart, Hangzhou Alltest Biotech Co ranks #999999 out of 336 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Hangzhou Alltest Biotech Co has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Alltest Biotech Co's Buyback Yield % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Hangzhou Alltest Biotech Co ranks #999999 out of 336 companies for Buyback Yield %. This places Hangzhou Alltest Biotech Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Hangzhou Alltest Biotech Co and its competitors. Hangzhou Alltest Biotech Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Alltest Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Alltest Biotech Co (SHSE:688606) is currently considered Possible Value Trap. The stock's GF Value™ is ¥89.34, compared to a current price of ¥49.30 — trading 44.8% below its estimated fair value. The current Buyback Yield % is 0.00. Hangzhou Alltest Biotech Co's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Hangzhou Alltest Biotech Co (SHSE:688606), the current Buyback Yield % is 0.00 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou Alltest Biotech Co (SHSE:688606) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou Alltest Biotech Co stock appears to be undervalued.
The current stock price of ¥49.30 is trading 44.8% below its estimated GF Value™ of ¥89.34.
GuruFocus considers Hangzhou Alltest Biotech Co to be Possible Value Trap.
Key valuation signals for SHSE:688606:
Buyback Yield %: 0.00
GF Value™: ¥89.34 vs. price of ¥49.30 (44.8% below fair value)
No single metric tells the full story. See the SHSE:688606 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688606 has been successfully added to your 
